Clinical Efficacy, Immunogenicity, Clinical Tolerability and Assessment of Safety of gpASIT+TM Administered Orally, According to Two Administration Schedules, for the Prophylaxis of Seasonal Grass Pollen Rhinoconjunctivitis.

Trial Profile

Clinical Efficacy, Immunogenicity, Clinical Tolerability and Assessment of Safety of gpASIT+TM Administered Orally, According to Two Administration Schedules, for the Prophylaxis of Seasonal Grass Pollen Rhinoconjunctivitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Grass pollen allergy immunotherapy-BioTech Tools (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Therapeutic Use
  • Sponsors BioTech Tools
  • Most Recent Events

    • 13 Sep 2014 New source identified and integrated (European Clinical Trials Database record:EudraCT2010-023176-12)
    • 23 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top